Recursion Pharmaceuticals, Inc. (“ Recursion ”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, today ...

Recursion Pharmaceuticals is back in focus after analysts adjusted their price target to US$5.90, following earlier updates ...

The option triggered a $10 million milestone payment to Recursion, bringing total upfront and milestone payments received from Sanofi under the collaboration to $144 million; Recursion is eligible for ...

Leading Healthcare Investors, including Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, Driehaus Capital ...

Recursion Pharma launches a $200M equity offering and reports a Sanofi milestone but is rated a Hold on limited near-term ...

Generative AI is remarkably good at churning out slick, surface-level 3D renderings of everything from futuristic sports cars to conceptual... Read More ...

Recursion Pharmaceuticals is maintained at a "Hold" rating, pending further regulatory clarity and late-stage trial ...

AI improves itself and creates even better AI.Such technology is attracting attention as a realistic research topic. It is ...

Recursion Pharmaceuticals announced a $10 million milestone payment from Sanofi for a new drug candidate targeting ...

In their mad rush for profit and power, the tech oligarchs have unleashed artificial intelligence (AI) into nearly every ...

Elon Musk spent the early hours of October 15 teasing what sounds like Tesla's next major AI unveiling, telling followers ...